Table 1.
Clinicopathological features and sites of distant metastases for the 1,470 patients with esophageal cancer.
| Variable | Entire cohort | Distant lymph nodes | Bone | Brain | Liver | Lung | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | No | Yes | p | No | Yes | p | No | Yes | p | No | Yes | p | No | Yes | p | |
| AGE (YEARS) | ||||||||||||||||
| <50 | 133 | 74 (8.9) | 59 (9.3) | 0.802 | 98 (8.7) | 35 (10.2) | 0.405 | 124 (8.9) | 9 (11.8) | 0.383 | 56 (7.5) | 77 (10.6) | 0.041 | 92 (9.1) | 41 (8.9) | 0.917 |
| ≥50 | 1,337 | 759 (91.1) | 578 (90.7) | 1,028 (91.3) | 309 (89.8) | 1,270 (91.1) | 67 (88.2) | 687 (92.5) | 650 (89.4) | 919 (90.9) | 418 (91.1) | |||||
| GENDER | ||||||||||||||||
| Male | 1,235 | 699 (83.9) | 536 (84.1) | 0.905 | 944 (83.8) | 291 (84.6) | 0.738 | 1,170 (83.9) | 65 (85.5) | 0.712 | 607 (81.7) | 628 (86.4) | 0.014 | 864 (85.5) | 371 (80.8) | 0.025 |
| Female | 235 | 134 (16.1) | 101 (15.9) | 182 (16.2) | 53 (15.4) | 224 (16.1) | 11 (14.5) | 136 (18.3) | 99 (13.6) | 147 (14.5) | 88 (19.2) | |||||
| RACE/ETHNICITY | ||||||||||||||||
| White | 1,244 | 698 (83.8) | 546 (85.7) | 0.055 | 947 (84.1) | 297 (86.3) | 0.581 | 1,175 (84.3) | 69 (90.8) | 0.147 | 601 (80.9) | 643 (88.4) | <0.001 | 888 (87.8) | 356 (77.6) | <0.001 |
| Black | 153 | 99 (11.9) | 54 (8.5) | 122 (10.8) | 31 (9.0) | 150 (10.8) | 3 (3.9) | 95 (12.8) | 58 (8.0) | 84 (8.3) | 69 (15.0) | |||||
| Other | 73 | 36 (4.3) | 37 (5.8) | 57 (5.1) | 16 (4.7) | 69 (4.9) | 4 (5.3) | 47 (6.3) | 26 (3.6) | 39 (3.9) | 34 (7.4) | |||||
| LOCATION | ||||||||||||||||
| Upper | 59 | 30 (3.6) | 29 (4.6) | 0.033 | 42 (3.7) | 17 (4.9) | 0.414 | 58 (4.2) | 1 (1.3) | 0.707 | 45 (6.1) | 14 (1.9) | <0.001 | 34 (3.4) | 25 (5.4) | <0.001 |
| Middle | 176 | 109 (13.1) | 67 (10.5) | 129 (11.5) | 47 (13.7) | 167 (12.0) | 9 (11.8) | 120 (16.2) | 56 (7.7) | 99 (9.8) | 77 (16.8) | |||||
| Lower | 1,048 | 604 (75.5) | 444 (69.7) | 814 (72.3) | 234 (68.0) | 993 (71.2) | 55 (72.4) | 467 (62.9) | 581 (77.9) | 763 (75.5) | 285 (62.1) | |||||
| Overlapping | 187 | 90 (10.8) | 97 (15.2) | 141 (12.5) | 46 (13.4) | 176 (12.6) | 11 (14.5) | 111 (14.9) | 76 (10.5) | 115 (11.4) | 72 (15.7) | |||||
| HISTOLOGY | ||||||||||||||||
| SCC | 374 | 218 (26.2) | 156 (24.5) | 0.463 | 287 (25.5) | 87 (25.3) | 0.941 | 366 (26.3) | 8 (10.5) | 0.002 | 250 (33.6) | 124 (17.1) | <0.001 | 200 (19.8) | 174 (37.9) | <0.001 |
| AC | 1,096 | 615 (73.8) | 481 (75.5) | 839 (74.5) | 257 (74.7) | 1,028 (73.7) | 68 (89.5) | 493 (66.4) | 603 (82.9) | 811 (80.2) | 285 (62.1) | |||||
| GRADE | ||||||||||||||||
| G1 | 40 | 26 (3.1) | 14 (2.2) | 0.539 | 28 (2.5) | 12 (3.5) | 0.083 | 35 (2.5) | 5 (6.6) | 0.066 | 21 (2.8) | 19 (2.6) | 0.422 | 26 (2.6) | 14 (3.1) | 0.208 |
| G2 | 545 | 310 (37.2) | 235 (36.9) | 434 (38.5) | 111 (32.3) | 522 (37.4) | 23 (30.3) | 287 (38.6) | 258 (35.5) | 361 (35.7) | 184 (40.1) | |||||
| G3-4 | 885 | 497 (59.7) | 388 (60.9) | 664 (59.0) | 221 (64.2) | 837 (60.0) | 48 (63.1) | 435 (58.5) | 450 (61.9) | 624 (61.7) | 261 (56.9) | |||||
| TUMOR STAGE | ||||||||||||||||
| T1-2 | 635 | 388 (46.6) | 247 (38.8) | 0.003 | 482 (42.8) | 153 (44.5) | 0.584 | 594 (42.6) | 41 (53.9) | 0.052 | 291 (39.2) | 344 (47.3) | 0.002 | 441 (43.6) | 194 (42.3) | 0.627 |
| T3-4 | 835 | 445 (53.4) | 390 (61.2) | 644 (57.2) | 191 (55.5) | 800 (57.4) | 35 (46.1) | 452 (60.8) | 383 (52.7) | 570 (56.4) | 265 (57.7) | |||||
| REGIONAL LYMPH NODE STATUS | ||||||||||||||||
| Node negative | 330 | 274 (32.9) | 56 (8.8) | <0.001 | 247 (21.9) | 83 (24.1) | 0.394 | 315 (22.6) | 15 (19.7) | 0.561 | 124 (16.7) | 206 (28.3) | <0.001 | 214 (21.2) | 116 (25.3) | 0.08 |
| Node positive | 1,140 | 559 (67.1) | 581 (91.2) | 879 (78.1) | 261 (75.9) | 1,079 (77.4) | 61 (80.3) | 619 (83.3) | 521 (71.7) | 797 (78.8) | 343 (74.7) | |||||
AC, adenocarcinoma; G1, well-differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; SCC, squamous cell carcinoma; T, tumor.